Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular changes during AT/RT progression associated with epithelial-mesenchymal transition and extracellular matrix changes.

Acta neuropathologica·2026
Same author

Prevalence of diabetes mellitus in long-term cancer survivors treated with craniospinal irradiation.

Journal of the Endocrine Society·2026
Same author

Guidance for the Diagnosis and Treatment of Rare Embryonal and Sarcomatous Brain Tumors-a Report from the Central Nervous System-International Registry for Rare Embryonal and Sarcomatous Tumors German Society of Pediatric Oncology and Hematology Study Group.

Klinische Padiatrie·2026
Same author

Hetairos is a histology-based artificial intelligence model for predicting central nervous system tumor methylation subtypes.

Nature cancer·2026
Same author

Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all Ages.

Neuro-oncology·2026
Same author

Treatment effect heterogeneity of radiotherapy in localized Ewing sarcoma: A secondary analysis of the EURO-E.W.I.N.G. 99 and Ewing 2008 trial.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Mid-term reflections and the growing momentum of Neuro-Oncology.

Neuro-oncology·2026
Same journal

Inferring DNA Methylation Class from Digitized Pathology Images and AI: A Worthy and Timely Application with Room for Improved Clinical Performance.

Neuro-oncology·2026
Same journal

The clinical and molecular landscape of thalamic glioma.

Neuro-oncology·2026
Same journal

MAPK-driven glioma progression and reprogramming of the tumor-associated immune response.

Neuro-oncology·2026
Same journal

Tumor-Targeted pan-RAS Inhibition as a Novel Biologic Therapy for Diffuse Midline Glioma.

Neuro-oncology·2026
Same journal

Corrigendum to: Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.

Neuro-oncology·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2025

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

1.5K

Distinct relapse pattern across molecular ependymoma types.

Denise Obrecht-Sturm1, Melanie Schoof2, Alicia Eckhardt3,2

  • 1Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Neuro-Oncology
|August 22, 2024
PubMed
Summary
This summary is machine-generated.

Ependymoma (EPN) relapse patterns vary significantly by molecular subtype. Understanding these differences is crucial for tailoring surveillance and treatment strategies for pediatric and adult patients.

Keywords:
ependymomametastaticrecurrencerelapse

More Related Videos

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.0K
Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

2.7K

Related Experiment Videos

Last Updated: Jun 15, 2025

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

1.5K
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.0K
Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

2.7K

Area of Science:

  • Neuro-oncology
  • Molecular Pathology
  • Clinical Research

Background:

  • Ependymoma (EPN) is a heterogeneous tumor with distinct molecular subtypes.
  • Current understanding of relapse patterns for different EPN subtypes is limited.
  • This heterogeneity necessitates subtype-specific analysis of disease recurrence.

Purpose of the Study:

  • To comprehensively describe the relapse patterns of molecularly defined ependymoma subtypes.
  • To correlate DNA methylation and copy-number alterations with clinical relapse information.
  • To inform future clinical trial design and treatment strategies for EPN.

Main Methods:

  • Analysis of 269 relapsed intracranial ependymoma cases from European and North American cohorts.
  • Correlation of molecular data (DNA methylation, copy-number alterations) with clinical data.
  • Stratification by molecular subtype: PF-EPN-A, ST-EPN-ZFTA, PF-EPN-B, PF-EPN-SE, and ST-EPN-YAP.

Main Results:

  • Significant differences in time to relapse, metastatic patterns, and spinal cord involvement were observed among EPN subtypes.
  • PF-EPN-B and PF-EPN-SE showed later relapse times but varied post-relapse survival (PRS).
  • ST-EPN-YAP and PF-EPN-SE had no distant relapses; ST-EPN-YAP patients were successfully salvaged with radiotherapy at relapse.

Conclusions:

  • Ependymoma relapse patterns are entity-specific, impacting clinical outcomes.
  • Clinical trials, surveillance, and diagnostics should incorporate these subtype-specific relapse characteristics.
  • Personalized approaches are essential for optimizing EPN management.